Pharmaceutical Contract Manufacturing Market Growth Driven by Outsourcing

 The global pharmaceutical contract manufacturing market size was estimated at USD 141.74 billion in 2025 and is projected to reach USD 310.97 billion by 2033, growing at a CAGR of 10.45% from 2026 to 2033. The demand for contract manufacturing is gaining momentum due to a surge in clinical as well as commercial workflow realignment among pharmaceutical manufacturers. Increasing demand for cost-efficient drug production, rising pharmaceutical research activities, and growing focus on outsourcing manufacturing operations are also contributing significantly to market growth worldwide.

Pharmaceutical contract manufacturing involves outsourcing drug development, active pharmaceutical ingredient production, formulation development, packaging, and commercial manufacturing activities to specialized third-party manufacturing organizations. Pharmaceutical companies are increasingly relying on contract manufacturing organizations to optimize operational efficiency, reduce production costs, improve scalability, and accelerate product commercialization timelines. Growing demand for specialized manufacturing expertise and expanding production requirements for generic drugs, biologics, and specialty pharmaceuticals are supporting market expansion globally.

Download a free sample copy of the Pharmaceutical Contract Manufacturing market report to understand detailed coverage and inclusions in the final report

Key Market Trends & Insights

• North America pharmaceutical contract manufacturing industry held the largest share of 38.44% of the global market in 2025. The region’s dominance is supported by the presence of major pharmaceutical companies, advanced healthcare infrastructure, strong research and development activities, and increasing outsourcing of manufacturing operations. Pharmaceutical manufacturers across North America are increasingly partnering with contract manufacturing organizations to improve production flexibility and meet growing demand for pharmaceutical products. Rising investments in biotechnology and drug development are further contributing to market growth across the region.
• The pharmaceutical contract manufacturing in the U.S. is expected to grow significantly over the forecast period. The country continues to witness increasing pharmaceutical production activities, growing demand for advanced manufacturing capabilities, and rising investments in drug research and development. Pharmaceutical companies in the U.S. are increasingly outsourcing manufacturing functions to specialized service providers to improve operational efficiency and focus on core research activities. In addition, increasing demand for biologics, specialty drugs, and personalized medicines is supporting market expansion throughout the country.
• By service, the API manufacturing segment held the largest market share of 70.68% in 2025. Active pharmaceutical ingredient manufacturing is a critical component of pharmaceutical production, as APIs serve as the primary biologically active substances used in medications. Rising demand for high-quality APIs, increasing generic drug production, and growing pharmaceutical outsourcing activities are contributing significantly to the dominance of this segment. Pharmaceutical companies are increasingly relying on contract manufacturers for large-scale API production to ensure cost efficiency, regulatory compliance, and supply chain optimization.
• By product, the small molecule segment held the largest market share in 2025. Small molecule drugs continue to dominate the pharmaceutical industry due to their widespread use in the treatment of chronic diseases, infectious conditions, cardiovascular disorders, and neurological diseases. These drugs are generally easier to manufacture, store, and distribute compared to complex biologic therapies. Increasing demand for generic small molecule drugs and ongoing pharmaceutical research activities are supporting the growth of this segment within the pharmaceutical contract manufacturing market.

Looking for more specific insights? Customize this report to suite your business needs

Key Companies & Market Share Insights

Market players are undertaking various strategic initiatives, such as the launch of new product innovations, collaborations, partnerships, and mergers & acquisitions, to strengthen their service offering and provide a competitive advantage. For instance, in March 2024, Tonix Pharmaceuticals Holding Corp. mentioned that it has selected two CMOs including Almac Pharma Services, to potentially produce Tonmya for commercial use in the U.S. The company is excited to move its first internally developed program toward NDA submission & to collaborate with CMOs for commercial supply and potential launch of Tonmya.

Key Pharmaceutical Contract Manufacturing Companies:

• AbbVie Contract Manufacturing
• Almac Group
• Boehringer Ingelheim BioXcellence
• Catalent
• Dr. Reddy's Laboratories
• Fareva
• Fujifilm Diosynth Biotechnologies
• Jubilant HollisterStier
• Lonza Group
• Patheon (Thermo Fisher Scientific)
• Pfizer CentreOne
• Prakruti Life Science
• Recipharm
• Samsung Biologics
• Siegfried Holding AG
• Vetter Pharma
• WuXi AppTec

Explore Grand View Horizon to see global and regional level statistics related to the Pharmaceutical Contract Manufacturing Market

Grand View Research offers

• Focused market intelligence reports on specific geographies or high-growth segments.
• Extended forecast timelines for long-term planning.
• Competitor Benchmarking and Supply Chain Analysis
• Inclusion of regulatory and policy assessments.
• Inclusion of custom data models, KPIs, or applications unique to your business
• Specific high-impact Data Decks and Tables to support effective decision making
• And much more…

Looking for a report customized to your requirements? Explore our Custom Research Offering